Supplementary Figure 1 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

Zhiguang Li,Jing Jiang,Zibing Wang,Jinhua Zhang,Mingjie Xiao,Chunhui Wang,Yu Lu,Zhihai Qin

DOI: https://doi.org/10.1158/0008-5472.22373519

2023-01-01

Abstract:Supplementary Figure 1 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

What problem does this paper attempt to address?

Supplementary Figure 2 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

Zhiguang Li,Jing Jiang,Zibing Wang,Jinhua Zhang,Mingjie Xiao,Chunhui Wang,Yu Lu,Zhihai Qin

DOI: https://doi.org/10.1158/0008-5472.22373516

2023-01-01

Abstract:Supplementary Figure 2 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis
Supplementary Figure 3 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

Zhiguang Li,Jing Jiang,Zibing Wang,Jinhua Zhang,Mingjie Xiao,Chunhui Wang,Yu Lu,Zhihai Qin

DOI: https://doi.org/10.1158/0008-5472.22373513

2023-01-01

Abstract:Supplementary Figure 3 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis
Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Xiaohui Fan,Randall J. Brezski,Hui Deng,Pooja Dhupkar,Yun Q. Shi,Anneliese Gonzalez,Songlin Zhang,Michael A. Rycyzyn,William R. Strohl,Robert E. Jordan,Ningyan Zhang,Zhiqiang An

DOI: https://doi.org/10.1158/1535-7163.22501711

2023-01-01

Abstract:Figure S1: IdeS expression in BT474 breast cancer cells Figure S2: Detection of MMPs in cancer cell lysates and culture supernatant Figure S3: scIgG-T was not in the SKBR-3 cell culture medium Figure S4: Detection of immune cells infiltration in mice by flow cytometry.
Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Ли Шен,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael A. Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22490453.v1

2023-01-01

Abstract:EGFR-mutant NSCLC tumor cells with acquired resistance to an EGFR-TKI display augmented IL-6 gene expression.
Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494757.v1

2023-01-01

Abstract:EGFR-mutant NSCLC EGFR-independent tumor model is refractory to EGFR-TKI treatment.
Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Sonia A. Patel,Monique B. Nilsson,Yan Yang,Xiuning Le,Hai T. Tran,Yasir Y. Elamin,Xiaoxing Yu,Fahao Zhang,Alissa Poteete,Xiaoyang Ren,Li Shen,Jing Wang,Seyed Javad Moghaddam,Tina Cascone,Michael Curran,Don L. Gibbons,John V. Heymach

DOI: https://doi.org/10.1158/1078-0432.22494754

2023-01-01

Abstract:IL-6 modulates expression of NK receptor and their ligands in EGFR mutant tumors.
Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Zhiliang Ma,Wen Li,Shinichi Yoshiya,Yong Xu,Masaki Hara,Yosif El‐Darawish,Tzvetanka Markova,Kyosuke Yamanishi,Hiromichi Yamanishi,Hideaki Tahara,Yoshimasa Tanaka,Haruki Okamura

DOI: https://doi.org/10.1158/1078-0432.22459815.v1

2023-01-01

Abstract:Cytotoxic activity exhibited by PECs from pre-implanted mice receiving immune checkpoint blockade and/or IL-18
Endogenously Expressed IL-4Rα Promotes the Malignant Phenotype of Human Pancreatic Cancer in Vitro and in Vivo

Benno Traub,Lie Sun,Yongsu Ma,Pengfei Xu,Johannes Lemke,Stephan Paschke,Doris Henne-Bruns,Uwe Knippschild,Marko Kornmann

DOI: https://doi.org/10.3390/ijms18040716

IF: 5.6

2017-01-01

International Journal of Molecular Sciences

Abstract:Exogenous interleukin-4 (IL-4) has been demonstrated to affect the growth of different human malignancies including pancreatic cancer cells. The aim of our study was to determine the role of endogenously expressed IL-4-receptor-α-chain (IL-4Rα) in pancreatic cancer cells. IL-4Rα-suppression was achieved by generating Capan-1 cells stably expressing shRNA targeting IL-4Rα. The malignant phenotype was characterized by assessing growth properties, directional and non-directional cell movement in vitro and tumor growth in vivo. Signaling pathways were analyzed upon IL-4 and IL-13 stimulation of wildtype (WT) and control-transfected cells compared to IL-4Rα-knockdown cells. Silencing of IL-4Rα resulted in reduced anchorage-dependent cell growth (p < 0.05) and reduced anchorage-independent colony size (p < 0.001) in vitro. Moreover, cell movement and migration was inhibited. IL-4 and IL-13 stimulation of Capan-1-WT cells induced activation of similar pathways like stimulation with Insulin-like growth factor (IGF)-I. This activation was reduced after IL-4Rα downregulation while IGF-I signaling seemed to be enhanced in knockdown-clones. Importantly, IL-4Rα silencing also significantly suppressed tumor growth in vivo. The present study indicates that endogenously expressed IL-4 and IL-4Rα contribute to the malignant phenotype of pancreatic cancer cells by activating diverse pro-oncogenic signaling pathways. Addressing these pathways may contribute to the treatment of the disease.
Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Feng Xu,Jing Liu,Di Liu,Biao Liu,Min Wang,Zhiyuan Hu,Xuemei Du,Li Tang,Fuchu He

DOI: https://doi.org/10.1158/0008-5472.22399947.v1

2023-01-01

Abstract:PDF file - 31KB, Supplementary Figure 2 Determination of concentration of IL-6 and IL-10 within tumor.
Supplemental Material-Figure S5 from Blocking NF-κB is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer

Xiaomao Guo,Zheng Li,Jianxin Jiang,Yan Zhao,Xin Wang,Ming Shen,Feng Zhu,Rui Tian,Changcheng Shi,Meng Xu,Xu Li,Pingfa Feng,Hang Zhang,Yechen Feng,Yuan Xie,Xiaodong Xu,Jia Wang,Ruizhi He,Chencheng Xie,Jun Hu,Dawei Ye,Min Wang,Renyi Qin

DOI: https://doi.org/10.1158/1078-0432.22459142.v1

2023-01-01

Abstract:Figure S5: IL-18 promotes PC cell proliferation, invasion and metastasis.
Supplementary Figure S4 from TNFRSF19 Inhibits TGFβ Signaling Through Interaction with TGFβ Receptor Type I to Promote Tumorigenesis

Chengcheng Deng,Yuxin Lin,Xue-Kang Qi,Guangcun He,Yuchen Zhang,Hao-Jiong Zhang,Mingwei Xu,Feng Qian,Jin‐Xin Bei,Yi‐Xin Zeng,Feng Li

DOI: https://doi.org/10.1158/0008-5472.22419512.v1

2023-01-01

Abstract:Supplementary Figure S4 from TNFRSF19 Inhibits TGFβ Signaling through Interaction with TGFβ Receptor Type I to Promote Tumorigenesis
Supplementary Figure Legend from Tumor Apoptotic Bodies Inhibit CTL Responses and Antitumor Immunity Via Membrane-Bound Transforming Growth Factor-β1 Inducing CD8+ T-Cell Anergy and CD4+ Tr1 Cell Responses

Yufeng Xie,Ou Bai,Jinying Yuan,Rajni Chibbar,Karen Slattery,Yangdou Wei,Yulin Deng,Jim Xiang

DOI: https://doi.org/10.1158/0008-5472.22378448

2023-01-01

Abstract:Supplementary Figure Legend from Tumor Apoptotic Bodies Inhibit CTL Responses and Antitumor Immunity via Membrane-Bound Transforming Growth Factor-β1 Inducing CD8+ T-Cell Anergy and CD4+ Tr1 Cell Responses
Supplementary Figure 4 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384257

2023-01-01

Abstract:Supplementary Figure 4 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 5 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384254

2023-01-01

Abstract:Supplementary Figure 5 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 6 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384251

2023-01-01

Abstract:Supplementary Figure 6 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Figure 4 from Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

Dan Huang,Yan Ding,Ming Zhou,Brian I. Rini,David Petillo,Chao-Nan Qian,Richard Kahnoski,P. Andrew Futreal,Kyle A. Furge,Bin Tean Teh

DOI: https://doi.org/10.1158/0008-5472.22387305.v1

2023-01-01

Abstract:Supplementary Figure 4 from Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma
Supplementary Figure S3 from TNFRSF19 Inhibits TGFβ Signaling Through Interaction with TGFβ Receptor Type I to Promote Tumorigenesis

Chengcheng Deng,Yuxin Lin,Xue-Kang Qi,Guangcun He,Yuchen Zhang,Hao-Jiong Zhang,Mingwei Xu,Feng Qian,Jin‐Xin Bei,Yi‐Xin Zeng,Feng Li

DOI: https://doi.org/10.1158/0008-5472.22419515.v1

2023-01-01

Abstract:Supplementary Figure S3 from TNFRSF19 Inhibits TGFβ Signaling through Interaction with TGFβ Receptor Type I to Promote Tumorigenesis
Supplementary Figure 3 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384260.v1

2023-01-01

Abstract:Supplementary Figure 3 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts
Supplementary Fig. S9 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Yoshinaga Ito,Deng Pan,Wubing Zhang,Xixi Zhang,Tiffany Y. Juan,Jason W. Pyrdol,Oleksandr Kyrysyuk,John G. Doench,X. Shirley Liu,Kai W. Wucherpfennig

DOI: https://doi.org/10.1158/2159-8290.22674261

2023-01-01

Abstract:Supplementary Fig. S9 shows enhanced IFNg and TNFa expression by T cells and NK cells in Rnf31/Atg5-dKO tumors.
Supplementary Figure 2 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Sid P. Kerkar,Pawel Muranski,Andrew Kaiser,Andrea Boni,Luis Sanchez-Perez,Zhiya Yu,Douglas C. Palmer,Robert N. Reger,Zachary A. Borman,Ling Zhang,Richard A. Morgan,Luca Gattinoni,Steven A. Rosenberg,Giorgio Trinchieri,Nicholas P. Restifo

DOI: https://doi.org/10.1158/0008-5472.22384263

2023-01-01

Abstract:Supplementary Figure 2 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 1 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

Supplementary Figure 2 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

Supplementary Figure 3 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Endogenously Expressed IL-4Rα Promotes the Malignant Phenotype of Human Pancreatic Cancer in Vitro and in Vivo

Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplemental Material-Figure S5 from Blocking NF-κB is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer

Supplementary Figure S4 from TNFRSF19 Inhibits TGFβ Signaling Through Interaction with TGFβ Receptor Type I to Promote Tumorigenesis

Supplementary Figure Legend from Tumor Apoptotic Bodies Inhibit CTL Responses and Antitumor Immunity Via Membrane-Bound Transforming Growth Factor-β1 Inducing CD8+ T-Cell Anergy and CD4+ Tr1 Cell Responses

Supplementary Figure 4 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 5 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 6 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 4 from Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

Supplementary Figure S3 from TNFRSF19 Inhibits TGFβ Signaling Through Interaction with TGFβ Receptor Type I to Promote Tumorigenesis

Supplementary Figure 3 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Fig. S9 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Figure 2 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 1 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

Supplementary Figure 2 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

Supplementary Figure 3 from Endogenous Interleukin-4 Promotes Tumor Development by Increasing Tumor Cell Resistance to Apoptosis

Supplementary Figure Legends and Supplementary Figures 1 Through 4 from A Novel Therapeutic Strategy to Rescue the Immune Effector Function of Proteolytically Inactivated Cancer Therapeutic Antibodies

Supplementary Figure S1 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S3 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure S4 from IL6 Mediates Suppression of T- and NK-cell Function in EMT-associated TKI-resistant EGFR-mutant NSCLC

Supplementary Figure 4 from Augmentation of Immune Checkpoint Cancer Immunotherapy with IL18

Endogenously Expressed IL-4Rα Promotes the Malignant Phenotype of Human Pancreatic Cancer in Vitro and in Vivo

Supplementary Figure 2 from LSECtin Expressed on Melanoma Cells Promotes Tumor Progression by Inhibiting Antitumor T-cell Responses

Supplemental Material-Figure S5 from Blocking NF-κB is Essential for the Immunotherapeutic Effect of Recombinant IL18 in Pancreatic Cancer

Supplementary Figure S4 from TNFRSF19 Inhibits TGFβ Signaling Through Interaction with TGFβ Receptor Type I to Promote Tumorigenesis

Supplementary Figure Legend from Tumor Apoptotic Bodies Inhibit CTL Responses and Antitumor Immunity Via Membrane-Bound Transforming Growth Factor-β1 Inducing CD8+ T-Cell Anergy and CD4+ Tr1 Cell Responses

Supplementary Figure 4 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 5 from Tumor-Specific CD8&lt;sup&gt;+&lt;/sup&gt; T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 6 from Tumor-Specific CD8&lt;sup&gt;+&lt;/sup&gt; T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 4 from Interleukin-8 Mediates Resistance to Antiangiogenic Agent Sunitinib in Renal Cell Carcinoma

Supplementary Figure S3 from TNFRSF19 Inhibits TGFβ Signaling Through Interaction with TGFβ Receptor Type I to Promote Tumorigenesis

Supplementary Figure 3 from Tumor-Specific CD8+ T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Fig. S9 from Addressing Tumor Heterogeneity by Sensitizing Resistant Cancer Cells to T Cell–secreted Cytokines

Supplementary Figure 2 from Tumor-Specific CD8&lt;sup&gt;+&lt;/sup&gt; T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 5 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 6 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts

Supplementary Figure 2 from Tumor-Specific CD8<sup>+</sup> T Cells Expressing Interleukin-12 Eradicate Established Cancers in Lymphodepleted Hosts